EICHORPublic-registry site landscape for NCT04789200, “Phase 2 Study of NX9 for Delineation of Bowel Anatomy”, a GI Carcinoma study sponsored by Nextrast, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT04789200 (registry record) |
| Study title | Phase 2 Study of NX9 for Delineation of Bowel Anatomy |
| Official title | APhase 2 Open Label, Study to Evaluate Safety, Pharmacokinetics & Efficacy of Oral Contrast Agent, NX9 for Delineation of Bowel Anatomy at CT Imaging With/Without IV Contrast in Subjects With Cancer or GI Disease Typically Evaluated With CT |
| Sponsor | Nextrast, Inc. |
| Condition(s) | GI Carcinoma; GI Disorders |
| Phase | PHASE2 |
| Listed sites | 2 |
| Intervention(s) | NX9 Oral Contrast Agent |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT04789200.
Eichor generates a preliminary site-risk snapshot for NCT04789200 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
